Dr. Avery is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
525 E Micheltorena Street
Ste A
Santa Barbara, CA 93103Phone+1 805-963-1648
Summary
- Robert L. Avery, MD is the founder and CEO of California Retina Consultants, Santa Barbara CA. He received his medical degree from Johns Hopkins University and took his ophthalmology training there at the Wilmer Eye Institute. He completed a vitreoretinal fellowship at Duke University under Dr. Robert Machemer, Brooks McCuen, and Gene de Juan. Dr. Avery returned to Johns Hopkins as Assistant Chief of Service and head of the trauma unit. He later went on to found California Retina Consultants, which grew into one of the largest retina practices in California and recently merged with several other national practices to form Retina Consultants of America.During the growth and expansion of CRC, Dr. Avery continued clinical and basic science research, especially in the field of angiogenesis and VEGF. He and his colleges at CRC had a role in pioneering the clinical use of anti-VEGF agents for retinal diseases. He founded the California Retina Research Foundation, which currently has over 30 active clinical research trials ongoing.
D. Avery has received numerous honors and awards, including Senior honor awards from the American Academy of Ophthalmology and the American Society of Retina Specialists, where he also serves on the board of directors. He was the first recipient of the Ronald G. Michels Fellowship Award. He is a member of the American Academy of Ophthalmology, the Retina Society, the Macula Society, the American Society of Retinal Specialists, the Vit-Buckle Society, and the Association for Research in Vision and Ophthalmology. He is a member of the Medical Leadership Board of Retina Consultants of America.
Dr. Avery is the co-editor of Retina Today, and he has published over 90 peer-reviewed articles on retinal diseases. His interests include the development of improved retinal drugs and their delivery, and he holds patents in retinal drug delivery. He is a partner in two ophthalmology venture capital companies, and he is on the board of several start-up
Education & Training
- Johns Hopkins UniversityResidency, Ophthalmology, 1988 - 1993
- Santa Barbara Cottage HospitalInternship, Internal Medicine, 1987 - 1988
- Johns Hopkins University School of MedicineClass of 1987
Certifications & Licensure
- CA State Medical License 1993 - 2025
- NC State Medical License 1991 - 2003
- MD State Medical License 1992 - 1994
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Join now to see all
Clinical Trials
- Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema Start of enrollment: 2005 Jun 01
- Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab Start of enrollment: 2011 Jul 01
- Analysis of Aqueous and Vitreous Humor Start of enrollment: 2015 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 143 citationsSubretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments TrialsAlex S. Willoughby, Gui-Shuang Ying, Cynthia A. Toth, Maureen G. Maguire, Russell Burns
Ophthalmology. 2015-09-01 - 57 citationsRetinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy.Hisashi Yokomizo, Yasutaka Maeda, Kyoungmin Park, Allen C. Clermont, Sonia L. Hernandez
Science Translational Medicine. 2019-07-03 - 42 citationsThe real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.Arshad M Khanani, Aamir A Aziz, Hannah Khan, Ashwin Gupta, Ohidul Mojumder
Eye. 2023-12-01
Press Mentions
- Market Cap of EyePoint Pharmaceuticals Inc. [EYPT] Reaches 65.23M – Now What?November 27th, 2020
- EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4November 19th, 2020
- REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of in-Office Delivery Platform for RGX-314September 4th, 2019
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: